NVRO Share Price Performance
US$5.84
1.49 (34.25%)
10.6% undervalued intrinsic discount
US$6.53
Fair Value
Price US$5.84
AnalystConsensusTarget US$6.53
Fair ValueUS$6.53
Share Pricen/a
Nevro Corp. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
NVRO Community Narratives
AN
Fair Value US$6.53 10.6% undervalued intrinsic discount
Restructuring And AI Trials Will Advance Spinal Cord Stimulation
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Restructuring And AI Trials Will Advance Spinal Cord Stimulation
Key Takeaways Strategic expense management and resource reallocation could enhance profitability and revenue, particularly through improved net margins and increased U.S. market activity. Innovative AI technology and regulatory approvals aim to expand market penetration and international reach, potentially boosting revenue and competitive positioning.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6.53
10.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
3.33% p.a.
Profit Margin
12.99%
Future PE
5.94x
Price in 2028
US$8.37
Trending Discussion
Recently Updated Narratives
AN
Restructuring And AI Trials Will Advance Spinal Cord Stimulation
Fair Value: US$6.53 10.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nevro Corp. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- -2.99
- 65.98%
- -27.77%
- 97.7%
About NVRO
- Founded
- 2006
- Employees
- 1099
- CEO
- WebsiteView website
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California.
